Item 1.01 Entry into a Material Definitive Agreement.

In connection with the execution of the Business Combination Agreement, AEON Biopharma, Inc. ("AEON") and Priveterra Acquisition Corp. ("Priveterra") entered into interim financing letter agreements for an aggregate amount of $20 million (the "Letter Agreements") with certain investors (the "Investors"), the terms of which provide for the sale and issuance to the Investors of an issued security that will be exchanged or converted at the closing of the Business Combination Agreement (the "Closing") into Class A Common Stock of Priveterra at a purchase price of $7.00 per Priveterra share. The Letter Agreements will terminate upon the earliest of (a) such date and time as the Business Combination Agreement is validly terminated, (b) upon mutual written agreement of each of the parties to the Letter Agreements, (c) at any time upon the election of Priveterra and AEON at their sole discretion and (d) nine months from the date of the Letter Agreements if the closing of the Business Combination Agreement has not occurred.

The foregoing description of the Letter Agreements is not complete and is qualified in its entirety by reference to the Letter Agreements, the form of which is attached as Exhibit 10.1 to this Current Report and incorporated herein by reference.





                                       2

Item 9.01 Financial Statements and Exhibits.






(d) Exhibits



Exhibit
  No.                                Description

  10.1     Form of Letter Agreement
104      Cover Page Interactive Data File (formatted in Inline XBRL document)




                                       3

© Edgar Online, source Glimpses